CagriSema
Also known as: Cagrilintide + Semaglutide · CagriSema combo
A fixed-combination metabolic agent that pairs the amylin analog cagrilintide with the GLP-1 agonist semaglutide to act on appetite and satiety through two complementary pathways.
Class
Amylin analog + GLP-1 agonist combination
Default unit
mg
Common route
Subcutaneous
Typical half-life
Long-acting (both components ~7 days)
Frequency
Once weekly
Commonly associated areas
Illustrative map of the body systems CagriSema is most often discussed in relation to. Relative emphasis only — not a measure of efficacy or a medical claim.
Proposed mechanisms / pathways
What is CagriSema?
CagriSema is a fixed-dose combination of two peptides: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. The idea behind pairing them is that amylin and GLP-1 signaling influence appetite through different but complementary routes, so the combination is studied as a single weekly metabolic agent rather than as two separate tools. Both components are long-acting, which is why it is associated with once-weekly dosing.
How it is thought to work
The two components are thought to act on appetite and satiety in parallel. The GLP-1 side is reported to support insulin release when blood sugar is high, slow gastric emptying, and reduce hunger signaling in the brain, while the amylin side is thought to promote a sense of fullness and help regulate food intake. Combining them is studied on the premise that two satiety pathways together may have a more pronounced effect on appetite than either alone — though individual responses vary and the science is still evolving.
Educational only — not medical advice
CagriSema is an investigational combination still under clinical study and is not a general-use product. Nothing here is a recommendation, dose, or medical claim — speak with a qualified healthcare provider about any metabolic protocol.
Tracking CagriSema in LynkDose
A combination like CagriSema is typically titrated over weeks, so record-keeping is where LynkDose helps most. Log each weekly dose with its date, mark when the dose steps up, do a consistent weekly weigh-in, and note appetite and any side effects. With that history in one place, a plateau or a change in tolerance becomes something you can see and discuss rather than guess at.
Commonly discussed for
- Appetite and craving regulation
- Weight-management protocols under medical supervision
- Combined GLP-1 and amylin approaches
Often stacked: CagriSema is itself a combination of cagrilintide and semaglutide, so it is generally used as a single agent rather than stacked further.
How to track CagriSema in LynkDose
Because CagriSema is a weekly, titrated combination, logging the date of every dose step alongside a consistent weekly weigh-in lets you connect changes in appetite, weight, and side effects to a specific stage of the protocol.
Deeper read: Tracking GLP-1 Peptides (Semaglutide & Tirzepatide)
Frequently asked questions
What is CagriSema?
A fixed-combination metabolic agent that pairs the amylin analog cagrilintide with the GLP-1 agonist semaglutide to act on appetite and satiety through two complementary pathways.
What is CagriSema commonly used for?
CagriSema is most commonly discussed in the context of appetite and craving regulation, weight-management protocols under medical supervision, and combined GLP-1 and amylin approaches. This is educational context, not medical advice.
How do you track CagriSema?
Because CagriSema is a weekly, titrated combination, logging the date of every dose step alongside a consistent weekly weigh-in lets you connect changes in appetite, weight, and side effects to a specific stage of the protocol.
Is CagriSema approved or medically recommended?
No. This page is educational only and is not medical advice. Many peptides are research compounds not approved for general human use. Always consult a qualified healthcare provider before making health decisions.
Research & references
For primary research and chemical data, search these databases. Entries here are educational summaries, not citations of specific findings.
Not medical advice
This page is educational and does not recommend, prescribe, or dose any compound. Many peptides are research chemicals not approved for general human use. Always consult a qualified healthcare provider and follow the laws in your area.